Navigation Links
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Date:8/17/2010

INDIANAPOLIS, Aug. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

The company's decision does not affect the ongoing clinical trials of solanezumab, Lilly's other compound in Phase III trials as a potential Alzheimer's treatment. While both drugs focus on amyloid-beta proteins, which are believed to play a critical role in Alzheimer's disease, they have different mechanisms of action. Lilly also has two other compounds in earlier stages of clinical development; those studies are not affected by today's announcement.

In two pivotal Phase III trials, semagacestat was compared with placebo in more than 2,600 patients with mild-to-moderate Alzheimer's disease. Lilly has now reviewed data from a pre-planned interim analysis of semagacestat studies. This interim analysis showed that, as expected, cognition and the ability to complete activities of daily living of placebo-treated patients worsened.  However, by these same measures, patients treated with semagacestat worsened to a statistically significantly greater degree than those treated with placebo. In addition, data showed semagacestat is associated with an increased risk of skin cancer compared with those who received placebo.

"This is disappointing news for the millions of Alzheimer's patients and their families worldwide who anxiously await a successful treatment for this devastating illness," said Jan M. Lundberg, Ph.D., Executive Vice President, Science and Technology, and President, Lilly Research Laboratories. "This is a se
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets has announced the addition of the ... to their offering. This report analyzes the ... following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... Elbit Imaging Ltd. ("EI" or ... today that Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: ... holds approximately 86% of the voting power, announced that ... Elbit Medical holds approximately 30.8% of the voting power ... shareholders (including Elbit Medical), signed Option and Investment Agreements ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3
... to the FDA, LAUSANNE, Switzerland, November ... development specialist that,focuses on serious medical conditions ... its Canadian affiliate, filed its Complete,Response to ... States (U.S.),Food and Drug Administration (FDA) for ...
... ANTIPOLIS, France, November 4 NicOx,S.A. (Euronext Paris: ... patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the ... of escalating,doses of naproxcinod and naproxen in osteoarthritis ... was the mean 24-hour,ambulatory systolic blood pressure (SBP) ...
Cached Medicine Technology:Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 2Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 2NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 4
(Date:8/19/2014)... August 20, 2014 Top10BestSEOHosting.com has ... JustHost are the recommended suppliers for the webmasters ... hosting products. , According to the senior spokesman ... the most affordable hosting products on the market ... offer a variety of online deals when service ...
(Date:8/19/2014)... August 19, 2014 “ Inbox Blueprint ... course designed to provide users with the tools necessary ... marketing techniques and strategies. The course which was ... of excitement throughout the internet marketing world. The commotion ... HonestyFirstReviews.com's Tiffany Hendricks prompting an updated review of the ...
(Date:8/19/2014)... August 19, 2014 Horizon Blue Cross Blue ... Morgan Hoffmann are once again teaming up during The ... cause through a Walking Challenge, and Horizon BCBSNJ will be ... a course challenge of their own. , Horizon BCBSNJ, the ... is making a $5,000 donation to the New Jersey Golf ...
(Date:8/19/2014)... (HealthDay News) -- Lupus and other rheumatic diseases ... seizures, which can delay a correct diagnosis for ... rheumatic diseases can also cause these types of ... Center in Maywood, Ill. Rheumatic disorders include ... soft tissues, such as lupus, systemic vasculitis and ...
(Date:8/19/2014)... 2014 Grande Naturals, LLC is ... of the 2014 Independent Cosmetics Manufacturers & Distributors ... place position in “Product Innovation; Product Color Cosmetic” ... also includes a lash enhancement serum, GrandeLINER™. ... technology. , This all-new eyeliner is ...
Breaking Medicine News(10 mins):Health News:Fatcow Awarded As One of the Best Web Hosting Suppliers at Top10bestseohosting.com 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3
... today that it has dosed its first patient in ... ALT-2074, its lead glutathione peroxidase mimetic, in diabetic ... at high risk for cardiovascular complications. , ... ability to lower inflammatory cardiovascular biomarkers in patients with ...
... (JCVI) today announced the results of work on genome ... bacteria into another type dictated by the transplanted chromosome. ... journal Science, by JCVI's Carole Lartigue, Ph.D. and colleagues, ... bacterial species, Mycoplasma capricolum into another, Mycoplasma mycoides Large ...
... Businesses that offer customers shisha water pipes to smoke tobacco ... smoking ban that comes into force in England on Sunday. ... the water pipes are variously called, dozens of restaurants will ... see their sole activity disappear. ,"It's a disaster, ...
... name, one might rhetorically ask. But Malaccan state authorities have ... after their region. And now the virus will carry some ... announced last week they discovered a new virus likely carried ... called it the Melaka Virus, using the name of the ...
... with most other developing countries, plastic bags have become a terrible ... to be spiraling out of control, the government has announced a ... Uganda they are called buveera , and they are everywhere. ... organized dump like the one at Chitezi in Ugandan capital Kampala. ...
... found that nonsmoking restaurant and bar employees absorb a ... in places where they had to breathe tobacco smoke ... in the body only as a result of using ... the Multnomah County Health Department and Oregon Department of ...
Cached Medicine News:Health News:Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 3Health News:Mealaka Virus Will Have a New Name 2Health News:Uganda Bans Plastic Bags, Still a Tough Battle Lies Ahead 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: